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Abstract
Background: Six hospitals instituted a voluntary, system-wide, pathway for community acquired pneumonia (CAP).
We proposed this study to determine the impact of pathway antibiotics on patient survival, hospital length of stay
(LOS), and total hospital cost.
Methods: Data were collected for adults from six U.S. hospitals with a principal CAP discharge diagnosis code, a
chest infiltrate, and medical notes indicative of CAP from 2005-2007. Pathway and non-pathway cohorts were
assigned according to antibiotics received within 48 hours of admission. Pathway antibiotics included levofloxacin
750 mg monotherapy or ceftriaxone 1000 mg plus azithromycin 500 mg daily. Multivariable regression models
assessed 90-day mortality, hospital LOS, total hospital cost, and total pharmacy cost.
Results: Overall, 792 patients met study criteria. Of these, 505 (64%) received pathway antibiotics and 287 (36%)
received non-pathway antibiotics. Adjusted means and p-values were derived from Least Squares regression
models that included Pneumonia Severity Index risk class, patient age, heart failure, chronic obstructive pulmonary
disease, and admitting hospital as covariates. After adjustment, patients who received pathway antibiotics
experienced lower adjusted 90-day mortality (p = 0.02), shorter mean hospital LOS (3.9 vs. 5.0 days, p < 0.01), lower
mean hospital costs ($2,485 vs. $3,281, p = 0.02), and similar mean pharmacy costs ($356 vs. $442, p = 0.11).
Conclusions: Pathway antibiotics were associated with improved patient survival, hospital LOS, and total hospital
cost for patients admitted to the hospital with CAP.
Background
The Infectious Diseases Society of America (IDSA), in
conjunction with the American Thoracic Society (ATS),
has published guidelines for the empiric treatment of
CAP in adults [1]. Regarding ward patients, these guide-
lines advocate fluoroquinolone monotherapy or combi-
nation therapy with a beta-lactam plus a macrolide [1].
The 2007 guidelines were the first to specify a dose for
one of the fluoroquinolones (i.e., levofloxacin 750 mg
daily) [1]. Though not explicitly stated in the guidelines,
it is known from the pharmacokinetic-pharmacodynamic
(PK-PD) literature that higher daily fluoroquinolone
doses allow for greater antibiotic lung penetration [2].
Theoretically, the use of PK-PD based dosing should
result in additional patient benefits beyond those seen
with previous versions of the guidelines which did not
specify PK-PD based dosing [3]. This study aimed to test
this theory by comparing health and economic outcomes
for CAP patients treated according to a clinical pathway
to those patients not treated according to the pathway.
Methods
The study setting was a six-hospital health-system in
Austin, TX and its surrounding communities. In 2004,
these hospitals began to participate in the Center for Med-
icare and Medicaid Services (CMS) Pneumonia Core Mea-
sures. Staff and quality control personnel discovered
suboptimal compliance with guideline-endorsed initial
antibiotics. Therefore, a multi-disciplinary, disease-state
management team designed and implemented a voluntary,
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system-wide clinical pathway for the management of hos-
pitalized CAP patients in 2005. The pathway included
standard orders for antibiotic selection, including levoflox-
acin 750 mg daily or ceftriaxone 1000 mg plus azithromy-
cin 500 mg daily. The implementation of this pathway led
to antibiotic streamlining and set the stage for this com-
parative-effectiveness evaluation.
This study was approved by institutional review
boards (IRB) at two universities (The University of
Texas at Austin and The University of Texas Health
Science Center at San Antonio) and one central IRB
representing all six hospitals (Seton Family of Hospitals,
Brackenridge Hospital). Data were extracted from medi-
cal charts for adults (age 18 years or older) with a prin-
cipal discharge diagnosis of pneumonia (ICD-9-CM
codes 481-484 and 486) between January 2005 and
December 2007. To minimize the impact of coding
errors, only patients with a clinical diagnosis of pneu-
monia (medical progress notes) and documentation of a
chest infiltrate (radiology notes) were included. Patients
were excluded if they had risk factors for healthcare-
associated pneumonia (HCAP), which included the
following: admission from a nursing home or other
long-term care facility, transfer from another acute care
hospital, dialysis, hospital admission in the last 90 days,
or indwelling catheter or percutaneous medical device.
Patients were also excluded if they were immunocom-
promised (e.g., history of HIV/AIDS, transplant, or cur-
rent chemotherapy), experienced an abbreviated stay
(e.g., discharged to another acute care hospital, left
against medical advice, were hospitalized for only 1 day,
or died on day 1 of admission), or were admitted
directly to the intensive care unit (ICU). Finally, patients
were excluded if they had renal disease or an estimated
creatinine clearance (CrCl) less than 50 mL/min. CrCl
was estimated using the Cockcroft Gault equation. Ideal
body weight was used for patients with a body mass
index more than 30 kg/m2; whereas, actual body
weight was used for patients with a body mass index of
30 kg/m2 or less.
Data collection included information regarding admis-
sion year, facility, admitting service, patient demographics,
past medical history, past social history, antibiotics pre-
scribed during hospitalization and at discharge, daily vital
signs, culture results, hospital LOS, total pharmacy costs,
and total hospital costs. Severity of illness was determined
according to the Pneumonia Severity Index (PSI), a well-
validated rule that includes patient history, comorbidities,
presenting vital signs and symptoms, and baseline labora-
tory and diagnostic test results [4]. Ninety-day mortality
was determined by linking to the United States Social
Security Death Index. This index enabled mortality track-
ing post-discharge.
Data and Statistical Analyses
The primary endpoint was 90-day mortality. Secondary
endpoints included hospital LOS, total hospital costs, and
total pharmacy costs. LOS was determined by the follow-
ing equation: LOS = (discharge date - admission date) +
1 day. Patients were divided into two subgroups on the
basis of antibiotics received during the first two days of
hospitalization: (1) pathway antibiotics or (2) non-path-
way antibiotics. Pathway antibiotics included levofloxacin
750 mg IV or PO daily or ceftriaxone 1000 mg IV plus
azithromycin 500 mg IV or PO daily. Patients who
received these antibiotics at higher doses were also
included in the pathway group. Patients who received
these antibiotics at lower doses, or alternative antibiotics,
were stratified to the non-pathway group. The following
characteristics were compared between the two groups:
age, sex, nine key comorbidities, substance abuse, severity
of illness, microbial etiology, 90-day mortality, hospital
LOS, and cost.
JMP 7.0® (SAS Corp, Cary, NC) was used for all statis-
tical analyses. Statistical comparisons with p-values <
0.05 were considered statistically significant. Chi-square,
Fisher’s Exact, and chi-square test for ordinal data were
used to compare discrete baseline variables, whereas the
Student’s t-test was used to compare continuous baseline
variables. A multivariable logistic regression model was
created to assess the impact of the pathway antibiotics on
90-day mortality. The other three outcomes (hospital
LOS, total hospital cost, and total pharmacy cost) were
assessed in multivariable Least Squares regression mod-
els. PSI risk class, age, heart failure, renal disease, chronic
obstructive pulmonary disease (COPD), and admitting
hospital were included as covariates in each of these
models.
Results
A total of 792 patients from six hospitals met study cri-
teria. Of these, 505 (64%) received pathway antibiotics
and 287 (36%) received other therapies. The most com-
mon pathway therapies included: levofloxacin 750 mg
daily (n = 336, 67%) and combination therapy with cef-
triaxone 1000 mg and azithromycin 500 mg, daily (n =
169, 33%). Common non-pathway therapies included
levofloxacin 500 mg daily (n = 188, 66%) and levofloxa-
cin 250 mg daily (n = 20, 7%). Pathway and non-path-
way groups were similar with respect to sex, race,
substance abuse history, and admitting service; however,
non-pathway patients were older, with more COPD
(Table 1).
Pathway and non-pathway groups differed with
respect to PSI risk class (p < 0.01), but were well-
balanced with respect to bacterial etiology (p = 0.2). The
proportions of pathway and non-pathway patients in
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each of the five PSI risk classes were as follows: I (15%
vs. 12%), II (44% vs. 34%), III (24% vs. 26%), IV (16% vs.
26%), and V (1% vs. 2%). Pathway and non-pathway
patients were frequently not cultured (42% vs. 39%) or
were culture-negative (44% vs. 51%). When a bacterial
pathogen was identified among pathway and non-path-
way patients, it was most frequently Streptococcus pneu-
moniae (8% vs. 5%), Haemophilus influenzae (2% vs.
1%), Staphylococcus aureus (2% vs. 2%), Moraxella cat-
arrhalis (1% vs. 0%), or other (1% vs. 2%).
Crude 90-day mortality was significantly lower in
patients who received pathway antibiotics versus non-
pathway antibiotics (1.4% vs. 4.5%, p < 0.01). This find-
ing was also statistically significant in an adjusted logis-
tic regression model that included PSI risk class, patient
age, heart failure, COPD, and admitting hospital as
covariates (p = 0.02).
Mean hospital LOS (4.9 vs. 6.0 days, p < 0.01) and total
hospital costs ($3,184 vs. $4,168, p < 0.01) were signifi-
cantly less for patients treated with pathway vs. non-
pathway therapies; however, total pharmacy costs ($528
vs. $611, p = 0.12) were similar. Adjusted means and
p-values were derived from Least Squares regression
models that included PSI risk class, patient age, heart fail-
ure, COPD, and admitting hospital as covariates.
Adjusted mean hospital LOS was significantly shorter for
patients treated with pathway vs. non-pathway therapies
(3.9 vs. 5.0 days, p < 0.01) (Figure 1). Adjusted hospital
costs were lower with pathway antibiotics ($2,485 vs.
$3,281, p = 0.02) and adjusted total pharmacy costs were
similar ($356 vs. $442, p = 0.11) (Figure 2). These results
demonstrate that, on average, the pathway resulted in
one day shorter time to hospital discharge and a reduced
total hospital cost of $796 per patient. This represents a
potential difference of 9 lives saved, 287 hospital days
saved, and $228,452 saved if all of the 287 patients in the
non-pathway group had been treated with pathway
antibiotics.
Discussion
This study demonstrates that pathway antibiotics are
associated with improved survival, shorter hospital LOS,
and reduced total hospital cost. This pathway is unique
in that it uses PK-PD dosing. In so doing, this study
goes beyond traditional guideline-concordant studies by
examining antibiotic dose and regimen, rather than anti-
biotic choice alone. Our chief finding was a reduction in
mortality for patients who received pathway antibiotics.
We also observed a decrease in hospital LOS and total
hospital costs in CAP patients treated with pathway
antibiotics, despite similar total pharmacy costs. Redu-
cing LOS may have other benefits including reduced
Table 1 Patient demographics by initial antibiotic
regimen *, †
Characteristic Pathway Non-Pathway p-value
(n = 505) (n = 287)
Age (yrs), median (IQR) 58 (45-71) 68 (51-81) <0.01
Sex
Male 46% 40% 0.1
Female 54% 60% –
Race
White 68% 71% 0.5
Hispanic 17% 14% –
Black 11% 10% –
Other 4% 5% –
Comorbidities
Neoplastic disease 10% 13% 0.2
Liver disease 6% 8% 0.2
Heart failure 10% 14% 0.06
Cerebrovascular disease 5% 7% 0.4
Diabetes mellitus 24% 21% 0.5
COPD 19% 26% 0.02
Asthma 15% 16% 0.9
Depression 9% 10% 0.5
Social history
Tobacco (smoker) 28% 30% 0.5
Alcohol 16% 15% 0.6
Intravenous drug abuse 3% 3% 0.9
Admitting Service
Medicine 92% 92% 0.9
Other 8% 8% –
* Pathway = levofloxacin 750 mg intravenous or oral daily OR ceftriaxone
1000 mg intravenous plus azithromycin 500 mg intravenous or oral daily OR
either of these antibiotic regimens at higher doses; Non-pathway = these
antibiotics at lower doses OR alternative antibiotics; COPD = chronic
obstructive pulmonary disease.
† The following statistical tests were used: Chi-square (sex, race, individual
comorbidities, social history, and admitting service) and Student’s t-test (age).
5.0
3.9
0.0 1.0 2.0 3.0 4.0 5.0 6.0
Hospital LOS (Days)
Non Pathway (n=287) Pathway (n=505)
p<0.01
Figure 1 Adjusted least squares mean hospital length of stay
by initial antibiotic regimen*. * The adjusted mean and p-value
were derived from a least squares regression model that included
PSI risk class, patient age, heart failure, chronic obstructive
pulmonary disease, and admitting hospital as covariates.
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invasive catheter use, decreased risk of nosocomial dis-
eases, and enhanced patient quality of life [5,6].
Fluoroquinolone monotherapy has been a first-line
recommendation for the empiric treatment of hospital
ward patients in several versions of the CAP guidelines
[1,3]; however, the 2007 IDSA/ATS guidelines were the
first to specify a levofloxacin dose of 750 mg daily [1].
The reason was not explicitly stated; however, the ratio-
nale for this recommendation can be surmised from
recent PK-PD and clinical literature touting the benefits
of levofloxacin 750 mg daily [2]. Fluoroquinolones are
considered to be concentration-dependent antibiotics,
meaning higher drug concentrations result in greater
rates and extent of microbial killing [7,8]. Favorable out-
comes have been associated with Cmax/MIC, though the
pharmacodynamic parameter most commonly correlated
with antibiotic efficacy is the 24-hour area under the
curve/MIC (AUC24/MIC) ratio [9,10]. For Gram-positive
infections, the optimal AUC24/MIC is 30 to 40 [11].
The approved dosing regimens for levofloxacin in CAP
are 500 mg daily for 7-14 days or 750 mg daily for 5 days.
An in vitro study by Lister examined the pharmacody-
namics of levofloxacin 500 mg and 750 mg against wild
type S. pneumoniae strains and ciprofloxacin resistant
strains [12]. In organisms that exhibited a higher MIC50,
the 750 mg dose eradicated the infective organism more
effectively than the 500 mg dose [12]. Dunbar et al. per-
formed a multicenter, randomized, double-blind investi-
gation comparing levofloxacin 750 mg daily for 5 days vs.
levofloxacin 500 mg daily for 10 days in patients with
mild to severe CAP [13]. Levofloxacin 750 mg daily
demonstrated comparable efficacy to 500 mg daily in
clinical success rates, with similar results seen in a sub-
group analysis of PSI class III/IV patients [14], as well as
in elderly patients [15]. However, in comparison to levo-
floxacin 500 mg, levofloxacin 750 mg was associated with
a significantly shorter time to fever reduction, faster
resolution of purulent sputum and a trend towards more
rapid IV to PO conversion with no significant increases
in adverse events [13,14,16,17]. Few studies have exam-
ined different dosage regimens of moxifloxacin, though
one demonstrated increased efficacy for 400 mg vs. 200
mg [18].
Beta-lactams, in combination with macrolides, have
also been a first-line recommendation for the empiric
treatment of hospital ward patients throughout several
versions of the CAP guidelines. The 2007 IDSA/ATS
guidelines do not specify antibiotic doses or dosing regi-
mens for any of the beta-lactams. We know from PK-PD
studies that beta-lactams demonstrate a time-dependent
mechanism for bacterial killing and the pharmacody-
namic parameter most closely associated with outcomes
is percent time above the MIC (%T>MIC). A %T>MIC of
approximately 40-50% of the dosing interval is usually
considered adequate [7]. Options to maximize the PK-PD
of beta-lactams include more frequent dosing, continu-
ous infusions, and extended infusion.
Macrolides were the final class of antibiotics used in our
pathway. The 2007 IDSA/ATS guidelines support the use
of azithromycin in combination with a beta-lactam as
first-line therapy for CAP ward patients, but the guidelines
do not specify a dose for azithromycin [1]. Approved azi-
thromycin doses for CAP include: 500 mg IV daily for
2 days, followed by 500 mg PO daily to complete a
7-10 day antibiotic course; 500 mg PO once followed by
250 mg PO daily for four more days; or a one-time dose of
2000 mg PO. The product labeling does not specify doses
for either outpatients or inpatients. Most studies of azi-
thromycin in combination with ceftriaxone for ward
patients have used an initial 500 mg IV dose for at least
two days followed by oral therapy, although guidelines
recommend either IV or PO azithromycin when used in
combination with beta-lactams [1,19-21]. Conventional
macrolides are considered to be time-dependent antibio-
tics; however, azithromycin is thought to be unique.
Azithromycin achieves extremely high, sustained concen-
trations in tissues and cells. Because of this, AUC24/MIC
is the PK-PD parameter associated with improved clinical
outcomes [22]. The target range of 25-30 has been corre-
lated with improved outcomes in patients with S. pneumo-
niae CAP [23].
Our study has strengths and limitations. First, we used
ICD-9-CM codes and chest radiographs to define our
cohort, thereby minimizing the impact of coding errors
introduced when using diagnosis codes alone. A second
strength is our meticulous exclusion of patients with
HCAP risk factors, which is directly responsible for the
lower PSI scores in our patients compared to the scores
seen in other published studies [24,25]. Not only are
HCAP patients at greater risk for S. aureus, but they are
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Figure 2 Adjusted least squares mean pharmacy and hospital
costs by initial antibiotic regimen*. * Adjusted means and
p-values were derived from least squares regression models that
included PSI risk class, patient age, heart failure, chronic obstructive
pulmonary disease, and admitting hospital as covariates.
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(MRSA) [26]. The primary limitation of our study is the
retrospective nature of the analysis, which limits the abil-
ity to detect differences in groups caused by unmeasured
variables. There were significant differences in the base-
line characteristics of the two populations. In the “path-
way” group, the patients were younger, with less heart
failure, and COPD. These factors were introduced as cov-
ariates in the multivariable regression models; however,
these factors may have been related to other, unmeasured
variables, and these might have influenced patient out-
comes. Antibiotic timing was not collected or evaluated,
but differences in antibiotic timing between the groups
could also influence the results. Positive cultures were
obtained for only 10% of our patients, which may limit
the validity of our pathogen distributions. Finally, this
study specifically compares those patients who were initi-
ally treated with pathway versus non-pathway antibiotics;
therefore, other aspects of treatment, such as time to
switch therapy, duration of treatment, and compliance
may have unknowingly influenced outcomes.
Conclusions
Pathway antibiotics were associated with improved
patient survival, hospital LOS, and total hospital cost for
patients admitted to the hospital with CAP.
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